Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 29, 2015 1:38 PM ET

Biotechnology

Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma Inc. operates as a biotherapeutics company that engages in the discovery and development of physiocrine-based therapeutics to address rare diseases. The company offers Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component. It provides its product for patients suffering from facioscapulohumeral muscular dystrophy. The company was incorporated in 2005 and is based in San Diego, California.

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

Phone:

858-731-8389

Fax:

858-731-8394

Key Executives for aTyr Pharma Inc.

Executive Chairman and Chief Executive Officer
Age: 54
President and Chief Operating Officer
Founder and Director
Age: 73
Chief Medical Officer
Associate Director of Discovery Research
Compensation as of Fiscal Year 2014.

aTyr Pharma Inc. Key Developments

aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris™ in FSHD

aTyr Pharma Inc. announced the European Commission has granted orphan drug designation to Resolaris for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Resolaris, an investigational new drug representing Physiocrine-based product candidate in the clinic, is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. aTyr previously announced the first patient study of Resolaris in adults with FSHD, a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients currently enrolling at multiple sites in the European Union (EU). EMA orphan designation is intended to encourage development of medicines for the diagnosis, treatment, or prevention of life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. Medicines that receive orphan designation are eligible for a number of incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized. Orphan designation is conferred following a positive opinion by the EMA's Committee for Orphan Medicinal Products (COMP).

aTyr Pharma Inc. Announces First FSHD Patient Study of Resolaris TM

aTyr Pharma announced its first FSHD patient clinical trial of Resolaris TM, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic. The study focuses on adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients at multiple sites in the European Union. The exploratory trial is designed to evaluate safety, tolerability, pharmacokinetics and the biological activity of Resolaris TM in adult patients with FSHD.

aTyr Pharma Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:00 AM

aTyr Pharma Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:00 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: John D. Mendlein, Executive Chairman and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
Beckman Coulter Genomics Inc. United States
Trifocal LLC United States
Pharmaceutical Experts, Inc. United States
Regulome Corp. United States
Renova Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact aTyr Pharma Inc., please visit www.atyrpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.